Followers | 840 |
Posts | 121697 |
Boards Moderated | 10 |
Alias Born | 09/05/2002 |

Monday, March 27, 2023 5:52:42 PM
https://www.businesswire.com/news/home/20230327005147/en
The HR for PFS was 0.54 in the pMMR subgroup and 0.30(!) in the dMMR subgroup.
The OS results are not disclosed in the PR, so they are presumably not mature. (OS was a secondary endpoint.)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRK News
- IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer • Business Wire • 06/18/2025 11:00:00 AM
- FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent • Business Wire • 06/13/2025 10:45:00 AM
- Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs • Business Wire • 06/12/2025 08:45:00 PM
- Merck Launches Final-Stage Trial of Dengue Vaccine for Children • IH Market News • 06/12/2025 01:51:02 PM
- Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate • Business Wire • 06/12/2025 10:45:00 AM
- U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season • Business Wire • 06/09/2025 07:11:00 PM
- Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia • Business Wire • 06/09/2025 10:45:00 AM
- Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference • Business Wire • 06/04/2025 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:25:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:22:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:21:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:18:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:05:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:58:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:55:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:53:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:51:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:49:42 PM
- KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC) • Business Wire • 05/31/2025 12:00:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/30/2025 01:56:39 PM
- Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations • Business Wire • 05/30/2025 12:05:00 PM
- Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial • Business Wire • 05/30/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2025 05:46:56 PM
- Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn • Business Wire • 05/29/2025 11:00:00 AM
Authentic Holdings Inc. Partnership with Swerve TV Debuts with Highly Successful 'Ring of Combat' Live Broadcast • AHRO • Jun 18, 2025 12:45 PM
ePIC Blockchain Signs LOI with A.R.T. Digital to Redefine Bitcoin Miner Design with Breakthrough Air-Cooling Technology • CGAC • Jun 18, 2025 12:41 PM
Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies • AVAI • Jun 17, 2025 8:00 AM
Cannabix Technologies Receives Notice of Allowance from USPTO for Contactless Breath Analysis • BLO • Jun 17, 2025 8:00 AM
A.R.T. Digital Holdings (OTC: CGAC) Secures Non-Dilutive Financing for George West Site Supporting NASDAQ: BTBT • CGAC • Jun 17, 2025 5:07 AM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM